Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Wagner, D; Fahrleitner-Pammer, A.
Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: Are they of any help?
Wien Med Wochenschr. 2010; 160(17-18): 452-457. Doi: 10.1007/s10354-010-0818-x
PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz
Fahrleitner-Pammer Astrid
Wagner Doris
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
The coupling of bone formation and resorption is mediated through the OPG/RANK/RANKL system. OPG and RANKL are mainly produced by osteoblasts but also a variety of other tissues. The binding of RANKL to RANK, its natural receptor which is expressed by osteoclasts, accelerates bone resorption. OPG acts as decoy receptor and prevents the interaction of RANKL with RANK and therefore leads to a decrease in activity, survival and proliferation of osteoclasts. Since assays for measurements of serum OPG and RANKL have become commercially available, intense research focused on serum OPG/RANKL levels in context with underlying disease, age, co-morbidities, bone density, and fractures has derived. This review aims to provide an overview if and to which extent serum OPG and RANKL levels may reflect bone metabolism in patients with osteoporosis and metabolic bone disease.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Body Mass Index -
Bone Density - physiology
Bone Diseases, Metabolic - diagnosis
Bone Resorption - blood
Bone and Bones - physiopathology
Cell Division - physiology
Cell Survival - physiology
Fractures, Spontaneous - diagnosis
Humans -
Liver - physiopathology
Osteoblasts - physiology
Osteoclasts - physiology
Osteogenesis - physiology
Osteoporosis - blood
Osteoprotegerin - blood
Predictive Value of Tests -
RANK Ligand - blood

© Med Uni Graz Impressum